Compare Stocks: OSUR, QDEL, CERS, and SMTI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.98 +4.9%	$2.80	$1.15 ▼ $3.47	$600.54M	1.81	3.09 million shs	2.49 million shs
OSUR OraSure Technologies	$3.84 -4.5%	$4.15	$2.08 ▼ $4.58	$264.84M	1	436,606 shs	582,448 shs
QDEL QuidelOrtho	$14.30 -5.2%	$15.80	$9.92 ▼ $35.58	$980.62M	0.68	1.52 million shs	917,336 shs
SMTI Sanara MedTech	$34.15 0.0%	$26.40	$16.05 ▼ $35.95	$313.77M	1.13	387,288 shs	625,484 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	0.00%	+26.81%	-7.17%	+27.35%	+124.06%
OSUR OraSure Technologies	0.00%	-5.19%	-3.03%	+28.00%	+34.74%
QDEL QuidelOrtho	0.00%	+16.45%	-21.60%	+38.57%	-47.19%
SMTI Sanara MedTech	0.00%	+0.15%	+34.87%	+62.16%	+6.99%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CERS Cerus	$2.98 +4.9%	$2.80	$1.15 ▼ $3.47	$600.54M	1.81	3.09 million shs	2.49 million shs
OSUR OraSure Technologies	$3.84 -4.5%	$4.15	$2.08 ▼ $4.58	$264.84M	1	436,606 shs	582,448 shs
QDEL QuidelOrtho	$14.30 -5.2%	$15.80	$9.92 ▼ $35.58	$980.62M	0.68	1.52 million shs	917,336 shs
SMTI Sanara MedTech	$34.15 0.0%	$26.40	$16.05 ▼ $35.95	$313.77M	1.13	387,288 shs	625,484 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CERS Cerus	0.00%	+26.81%	-7.17%	+27.35%	+124.06%
OSUR OraSure Technologies	0.00%	-5.19%	-3.03%	+28.00%	+34.74%
QDEL QuidelOrtho	0.00%	+16.45%	-21.60%	+38.57%	-47.19%
SMTI Sanara MedTech	0.00%	+0.15%	+34.87%	+62.16%	+6.99%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CERS Cerus	2.25	Hold	$4.00	34.23% Upside
OSUR OraSure Technologies	1.50	Reduce	$3.00	-21.88% Downside
QDEL QuidelOrtho	1.50	Reduce	$13.63	-4.72% Downside
SMTI Sanara MedTech	1.80	Reduce	$35.00	2.49% Upside

Current Analyst Ratings Breakdown

Latest OSUR, QDEL, CERS, and SMTI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2026	QDEL QuidelOrtho	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/11/2026	SMTI Sanara MedTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	SMTI Sanara MedTech	Freedom Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/30/2026	SMTI Sanara MedTech	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$35.00
7/30/2026	SMTI Sanara MedTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$36.00 ➝ $35.00
7/17/2026	QDEL QuidelOrtho	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	SMTI Sanara MedTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	QDEL QuidelOrtho	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$13.00 ➝ $18.00
7/1/2026	QDEL QuidelOrtho	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$11.00 ➝ $12.00
6/29/2026	QDEL QuidelOrtho	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
6/18/2026	CERS Cerus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CERS Cerus	$206.13M	2.91	N/A	N/A	$0.35 per share	8.51
OSUR OraSure Technologies	$115.02M	2.30	N/A	N/A	$4.61 per share	0.83
QDEL QuidelOrtho	$2.73B	0.36	$18.82 per share	0.76	$25.88 per share	0.55
SMTI Sanara MedTech	$103.12M	3.04	$0.59 per share	57.44	$0.86 per share	39.71

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CERS Cerus	-$15.63M	-$0.03	N/A	N/A	N/A	-3.06%	-10.19%	-3.14%	N/A
OSUR OraSure Technologies	-$68.73M	-$0.69	N/A	N/A	N/A	-43.70%	-19.09%	-16.26%	11/4/2026 (Estimated)
QDEL QuidelOrtho	-$1.13B	-$15.41	N/A	9.79	N/A	-39.20%	4.88%	1.63%	11/4/2026 (Estimated)
SMTI Sanara MedTech	-$37.56M	-$3.59	N/A	N/A	N/A	-29.15%	29.72%	2.84%	N/A

Latest OSUR, QDEL, CERS, and SMTI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SMTI Sanara MedTech	-$0.0250	-$0.05	-$0.0250	-$0.05	$28.95 million	$28.14 million
8/6/2026	Q2 2026	QDEL QuidelOrtho	-$0.0488	$0.13	+$0.1788	-$1.36	$618.72 million	$630.90 million
7/30/2026	Q2 2026	CERS Cerus	-$0.0133	-$0.01	+$0.0033	-$0.01	$62.90 million	$63.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CERS Cerus	N/A	N/A	N/A	N/A	N/A
OSUR OraSure Technologies	N/A	N/A	N/A	N/A	N/A
QDEL QuidelOrtho	N/A	N/A	N/A	N/A	N/A
SMTI Sanara MedTech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CERS Cerus	0.49	1.83	1.07
OSUR OraSure Technologies	N/A	8.88	7.68
QDEL QuidelOrtho	1.43	1.39	0.76
SMTI Sanara MedTech	5.86	2.58	2.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CERS Cerus	78.37%
OSUR OraSure Technologies	93.50%
QDEL QuidelOrtho	99.00%
SMTI Sanara MedTech	8.10%

Insider Ownership

Company	Insider Ownership
CERS Cerus	5.30%
OSUR OraSure Technologies	4.70%
QDEL QuidelOrtho	1.10%
SMTI Sanara MedTech	42.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CERS Cerus	290	201.52 million	190.84 million	Optionable
OSUR OraSure Technologies	840	68.97 million	65.73 million	Optionable
QDEL QuidelOrtho	6,500	68.57 million	67.82 million	Optionable
SMTI Sanara MedTech	60	9.19 million	5.33 million	Not Optionable

OSUR, QDEL, CERS, and SMTI Headlines

Recent News About These Companies

Walleye Capital LLC Makes New $719,000 Investment in Sanara MedTech Inc. $SMTI

2 hours ago | marketbeat.com

Sanara MedTech Inc

August 14 at 2:50 AM | money.usnews.com

Sanara MedTech Inc. (NASDAQ:SMTI) Given Consensus Rating of "Reduce" by Analysts

August 12, 2026 | americanbankingnews.com

Sanara MedTech Inc. (SMTI) Tops Q2 Earnings Estimates

August 11, 2026 | zacks.com

Sanara MedTech (NASDAQ:SMTI) Issues Quarterly Earnings Results, Misses Expectations By $0.03 EPS

August 11, 2026 | marketbeat.com

Sanara MedTech Inc. (SMTI) Releases Q2 2026 Earnings: Revenue Rises 8.9%

August 11, 2026 | quiverquant.comQ

Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)

August 11, 2026 | globenewswire.com

Sanara MedTech (SMTI) to Post Earnings on Wednesday

August 11, 2026 | americanbankingnews.com

Sanara MedTech Inc. (NASDAQ:SMTI) Receives Consensus Recommendation of "Reduce" from Analysts

August 7, 2026 | marketbeat.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—FBRX, LXFR, SMTI, and MKTX

August 6, 2026 | globenewswire.com

Sanara MedTech (NASDAQ:SMTI) Cut to Hold at Freedom Capital

August 6, 2026 | americanbankingnews.com

Sanara MedTech (SMTI) Expected to Post Earnings on Wednesday

August 5, 2026 | marketbeat.com

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX

August 4, 2026 | globenewswire.com

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)

August 4, 2026 | globenewswire.com

Sanara MedTech (NASDAQ:SMTI) Stock Rating Lowered by Freedom Capital

August 4, 2026 | marketbeat.com

Sanara MedTech Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sanara MedTech Inc. - SMTI

August 3, 2026 | businesswire.com

Sanara MedTech (NASDAQ:SMTI) Downgraded by Wall Street Zen to Buy

August 1, 2026 | marketbeat.com

MiMedx to acquire Sanara MedTech for $350M

July 31, 2026 | massdevice.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sanara MedTech Inc. (NASDAQ: SMTI)

July 30, 2026 | prnewswire.com

July 30, 2026 | globenewswire.com

Sanara MedTech (NASDAQ:SMTI) Downgraded to Neutral Rating by HC Wainwright

July 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OSUR, QDEL, CERS, and SMTI Company Descriptions

Cerus NASDAQ:CERS

$2.98 +0.14 (+4.93%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$2.98 0.00 (-0.03%)

As of 08/14/2026 07:53 PM Eastern

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

OraSure Technologies NASDAQ:OSUR

$3.84 -0.18 (-4.48%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$3.96 +0.12 (+3.13%)

As of 08/14/2026 07:34 PM Eastern

OraSure Technologies, Inc., together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of void urine samples; and microbiome laboratory testing and analytical services. In addition, the company provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Additionally, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is based in Bethlehem, Pennsylvania.

QuidelOrtho NASDAQ:QDEL

$14.30 -0.79 (-5.24%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$14.30 +0.00 (+0.03%)

As of 08/14/2026 07:49 PM Eastern

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.

Sanara MedTech NASDAQ:SMTI

$34.15 -0.01 (-0.03%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$34.14 -0.01 (-0.03%)

As of 08/14/2026 07:34 PM Eastern

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSUR, QDEL, CERS, and SMTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSUR, QDEL, CERS, and SMTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSUR, QDEL, CERS, and SMTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OSUR, QDEL, CERS, and SMTI Company Descriptions

Cerus NASDAQ:CERS

OraSure Technologies NASDAQ:OSUR

QuidelOrtho NASDAQ:QDEL

Sanara MedTech NASDAQ:SMTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OSUR, QDEL, CERS, and SMTI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OSUR, QDEL, CERS, and SMTI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OSUR, QDEL, CERS, and SMTI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OSUR, QDEL, CERS, and SMTI Company Descriptions

Cerus NASDAQ:CERS

OraSure Technologies NASDAQ:OSUR

QuidelOrtho NASDAQ:QDEL

Sanara MedTech NASDAQ:SMTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools